Proinsulin multi-peptide immunotherapy induces antigen-specific regulatory T cells and limits autoimmunity in a humanized model

Clinical and Experimental Immunology

Volumn 182, Issue 3, 2015, Pages 251-260

  Gibson, V B ^a   Nikolic, T ^b   Pearce, V Q ^a   Demengeot, J ^c   Roep, B O ^b   Peakman, M ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c INSTITUTO GULBENKIAN DE CIÊNCIA   (Portugal)

Author keywords

Antigens peptides epitopes; Autoimmunity; Diabetes; Regulatory T cells; T cells

Indexed keywords

AUTOANTIBODY; CD4 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 2 RECEPTOR ALPHA; PROINSULIN; TRANSCRIPTION FACTOR FOXP3; HLA DR4 ANTIGEN; HLA DRB1 ANTIGEN; HLA-DRB1*04:01 ANTIGEN; IL10 PROTEIN, MOUSE; INTERLEUKIN 10; PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ARTICLE; AUTOIMMUNITY; CD4+ CD25+ T LYMPHOCYTE; CONTROLLED STUDY; DENDRITIC CELL; DRUG MECHANISM; IMMUNOPHARMACOLOGY; IMMUNOREGULATION; IMMUNOTHERAPY; IN VIVO STUDY; INTERFERON PRODUCTION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROINSULIN MULTI PEPTIDE IMMUNOTHERAPY; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; ANIMAL; CELL PROLIFERATION; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DRUG EFFECTS; GENETICS; HUMAN; IMMUNOLOGY; PATHOLOGY; TRANSGENIC MOUSE;

ANIMALS; AUTOANTIBODIES; CELL PROLIFERATION; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; HLA-DR4 ANTIGEN; HLA-DRB1 CHAINS; HUMANS; IMMUNOTHERAPY; INTERFERON-GAMMA; INTERLEUKIN-10; MICE; MICE, TRANSGENIC; PEPTIDES; PROINSULIN; T-LYMPHOCYTES, REGULATORY;

EID: 84946472495     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12687     Document Type: Article

References (35)

1. Eisenbarth GS, Nayak RC, Rabinowe SL. Type I diabetes as a chronic autoimmune disease. J Diabet Complications 1988; 2:54-8.
2. von Herrath M, Peakman M, Roep B. Progress in immune-based therapies for type 1 diabetes. Clin Exp Immunol 2013; 172:186-202.
3. You S, Chatenoud L. Proinsulin: a unique autoantigen triggering autoimmune diabetes. J Clin Invest 2006; 116:3108-10.
4. Krishnamurthy B, Dudek NL, McKenzie MD et al. Responses against islet antigens in NOD mice are prevented by tolerance to proinsulin but not IGRP. J Clin Invest 2006; 116:3258-65.
5. Narendran P, Mannering SI, Harrison LC. Proinsulin-a pathogenic autoantigen in type 1 diabetes. Autoimmun Rev 2003; 2:204-10.
6. Mannering SI, Brodnicki TC. Recent insights into CD4+ T-cell specificity and function in type 1 diabetes. Expert Rev Clin Immunol 2007; 3:557-64.
7. Zhang L, Nakayama M, Eisenbarth GS. Insulin as an autoantigen in NOD/human diabetes. Curr Opin Immunol 2008; 20:111-8.
8. Peakman M, von Herrath M. Antigen-specific immunotherapy for type 1 diabetes: maximizing the potential. Diabetes 2010; 59:2087-93.
9. Alexander C, Ying S BKA., Larche . M, Fel d 1-derived T cell peptide therapy induces recruitment of CD4+ CD25+; CD4+ interferon-gamma+ T helper type 1 cells to sites of allergen-induced late-phase skin reactions in cat-allergic subjects. Clin Exp Allergy 2005; 35:52-8.
10. Wraith DC. Therapeutic peptide vaccines for treatment of autoimmune diseases. Immunol Lett 2009; 122:134-6.
11. Thrower SL, James L, Hall W et al. Proinsulin peptide immunotherapy in type 1 diabetes: report of a first-in-man Phase I safety study. Clin Exp Immunol 2009; 155:156-65.
12. Burton BR, Britton GJ, Fang H et al. Sequential transcriptional changes dictate safe and effective antigen-specific immunotherapy. Nat Commun 2014; 5:4741
13. Roep BO, Peakman M. Surrogate end points in the design of immunotherapy trials: emerging lessons from type 1 diabetes. Nat Rev Immunol 2010; 10:145-52.
14. She JX. Susceptibility to type I diabetes: HLA-DQ and DR revisited. Immunol Today 1996; 17:323-9.
15. Pociot F, McDermott MF. Genetics of type 1 diabetes mellitus. Genes Immun 2002; 3:235-49.
16. Kleijwegt FS, Laban S, Duinkerken G et al. Transfer of regulatory properties from tolerogenic to proinflammatory dendritic cells via induced autoreactive regulatory T cells. J Immunol 2011; 187:6357-64.
17. Unger WW, Laban S, Kleijwegt FS, van der Slik AR, Roep BO. Induction of Treg by monocyte-derived DC modulated by vitamin D3 or dexamethasone: differential role for PD-L1. Eur J Immunol 2009; 39:3147-59.
18. Ito K, Bian HJ, Molina M et al. HLA-DR4-IE chimeric class II transgenic, murine class II-deficient mice are susceptible to experimental allergic encephalomyelitis. J Exp Med 1996; 183:2635-44.
19. Arif S, Tree TI, Astill TP et al. Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. J Clin Invest 2004; 113:451-63.
20. Babaya N, Liu E, Miao D, Li M, Yu L, Eisenbarth GS. Murine high specificity/sensitivity competitive europium insulin autoantibody assay. Diabetes Technol Ther 2009; 11:227-33.
21. Ferreira GB, van Etten E, Verstuyf A et al. 1, 25-Dihydroxyvitamin D3 alters murine dendritic cell behaviour in vitro and in vivo. Diabetes Metab Res Rev 2011; 27:933-41.
22. Campbell JD, Buckland KF, McMillan SJ et al. Peptide immunotherapy in allergic asthma generates IL-10-dependent immunological tolerance associated with linked epitope suppression. J Exp Med 2009; 206:1535-47.
23. Pedotti R, Mitchell D, Wedemeyer J et al. An unexpected version of horror autotoxicus: anaphylactic shock to a self-peptide. Nat Immunol 2001; 2:216-22.
24. Liu E, Moriyama H, Abiru N, et al. Anti-peptide autoantibodies and fatal anaphylaxis in NOD mice in response to insulin self-peptides B:9-23 and B:13-23. J Clin Invest 2002; 110:1021-7.
25. Daniel D, Wegmann DR. Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23). Proc Natl Acad Sci USA 1996; 93:956-60.
26. Ehl S, Aichele P, Ramseier H et al. Antigen persistence and time of T-cell tolerization determine the efficacy of tolerization protocols for prevention of skin graft rejection. Nat Med 1998; 4:1015-9.
27. Patel D, Couroux P, Hickey P et al. Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: a randomized, placebo-controlled study. J Allergy Clin Immunol 2013; 131:103-9-e101-107.
28. Burton BR, Britton GJ, Fang H et al. Sequential transcriptional changes dictate safe and effective antigen-specific immunotherapy. Nat Commun 2014; 5:4741.
29. Peakman M, Dayan CM. Antigen-specific immunotherapy for autoimmune disease: fighting fire with fire? Immunology 2001; 104:361-6.
30. Verhoef A, Alexander C, Kay AB, Larche M. T cell epitope immunotherapy induces a CD4+ T cell population with regulatory activity. PLOS Med 2005; 2:e78.
31. Wraith DC. Role of interleukin-10 in the induction and function of natural and antigen-induced regulatory T cells. J Autoimmun 2003; 20:273-5.
32. Tarzi M, Klunker S, Texier C et al. Induction of interleukin-10 and suppressor of cytokine signalling-3 gene expression following peptide immunotherapy. Clin Exp Allergy 2006; 36:465-74.
33. Penna G, Roncari A, Amuchastegui S et al. Expression of the inhibitory receptor ILT3 on dendritic cells is dispensable for induction of CD4+Foxp3+ regulatory T cells by 1, 25-dihydroxyvitamin D3. Blood 2005; 106:3490-7.
34. Unger WW, Laban S, Kleijwegt FS, van der Slik AR, Roep BO. Induction of Treg by monocyte-derived DC modulated by vitamin D3 or dexamethasone: differential role for PD-L1. Eur J Immunol 2009; 39:3147-59.
35. Ureta G, Osorio F, Morales J, Rosemblatt M, Bono MR, Fierro JA. Generation of dendritic cells with regulatory properties. Transplant Proc 2007; 39:633-7.